Concord Biotech Board Approves Q2 Unaudited Results & Sets Bonus Share Record Date
Concord Biotech Limited approved its Q2 FY27 un-audited standalone and consolidated financial results. The company fixed November 04, 2026, as the record date for its 1:1 bonus share issue. The Board also reconstituted various committees. Total income for the quarter was ₹31,923.95 lakhs, with profit after tax at ₹6,957.20 lakhs.
The announcement includes financial results and a bonus issue, both of which are material events that can significantly impact the company's stock price and investor sentiment.
The company announced positive financial results and a bonus issue, which are generally viewed favorably by the market.
Concord Biotech Limited's Board of Directors, in a meeting held on Tuesday, October 27, 2026, approved the un-audited Standalone and Consolidated Financial Results for the second quarter and half year ended September 30, 2026. These results were reviewed and recommended by the Audit Committee. The company also fixed Wednesday, November 04, 2026, as the record date for the allotment of bonus equity shares, following a previous intimation on September 23, 2026. Additionally, the Board reconstituted the Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and Corporate Social Responsibility Committee.
The financial results indicate a total income of ₹31,923.95 lakhs for the quarter ended September 30, 2026, compared to ₹26,040.96 lakhs in the same period last year. Profit after tax for the quarter stood at ₹6,957.20 lakhs. For the half-year ended September 30, 2026, total income was ₹56,655.92 lakhs, with a profit after tax of ₹12,726.87 lakhs.
The company also disclosed an exceptional item of ₹327.54 lakhs related to the statutory impact of new labor codes, recognized as an incremental liability towards employee benefit obligations. The Board meeting commenced at 3:30 PM and concluded at 4:45 PM.
What to do with a filing like this
Concord Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Concord Biotech Limited. Read the original for the full detail.